Filters: Akiyama-2019b is   [Clear All Filters]
Del Bello D, Cha A, Sorbera M, et al. Real-world sustained virological response rates of sofosbuvir-containing regimens in patients coinfected with hepatitis C and HIV. Clin Infect Dis. 2016;62(12):1497-1504.
Delotte J, Barjoan E, Berrébi A, et al. Obstetric management does not influence vertical transmission of HCV infection: results of the ALHICE group study. J Matern Fetal Neonatal Med. 2014;27(7):664-670.
Denniston MM, Klevens RM, McQuillan GM, Jiles RB. Awareness of infection, knowledge of hepatitis C, and medical follow-up among individuals testing positive for hepatitis C: National Health and Nutrition Examination Survey 2001-2008. Hepatology. 2012;55(6):1652-1661.
Denniston MM, Jiles RB, Drobeniuc J, et al. Chronic hepatitis C virus infection in the United States, National Health and Nutrition Examination Survey 2003 to 2010. Ann Intern Med. 2014;160(5):293-300.
Des Jarlais D, Perlis T, Arasteh K, et al. Reductions in hepatitis C virus and HIV infections among injecting drug users in New York City, 1990-2001. AIDS. 2005;19 Suppl 3:S20-25.
Desnoyer A, Pospai D, Lê MPatrick, et al. Pharmacokinetics, safety and efficacy of a full dose sofosbuvir-based regimen given daily in hemodialysis patients with chronic hepatitis C. J Hepatol. 2016;65(1):40-47.
Deterding K, Spinner CD, Schott E, et al. Ledipasvir plus sofosbuvir fixed-dose combination for 6 weeks in patients with acute hepatitis C virus genotype 1 monoinfection (HepNet Acute HCV IV): an open-label, single-arm, phase 2 study. Lancet Infect Dis. 2017;17(2):215-222. doi:10.1016/S1473-3099(16)30408-X.
Di Bisceglie AM, Shiffman ML, Everson GT, et al. Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N Engl J Med. 2008;359(23):2429-2441.
Diaz-Castrillon CE, Huckaby LV, Witer L, et al. National trends and outcomes of heart-kidney transplantation using hepatitis C positive donors. Clin Transplant. 2022;36(4). doi:10.1111/ctr.14581.
Dienstag JL, Ghany MG, Morgan TR, et al. A prospective study of the rate of progression in compensated, histologically advanced chronic hepatitis C. Hepatology. 2011;54(2):396-405.
Dieperink E, Ho SB, Heit S, Durfee JM, Thuras P, Willenbring ML. Significant reductions in drinking following brief alcohol treatment provided in a hepatitis C clinic. Psychosomatics. 2010;51(2):149-156.
Dieterich D, Rockstroh JK, Orkin C, et al. Simeprevir (TMC435) with pegylated interferon/ribavirin in patients coinfected with HCV genotype 1 and HIV-1: a phase 3 study. Clin Infect Dis. 2014;59(11):1579-1587.
Dieterich D, Nelson M, Soriano V, et al. Faldaprevir and pegylated interferon alpha-2a/ribavirin in individuals co-infected with hepatitis C virus genotype-1 and HIV. AIDS. 2015;29(5):571-581.
Dietz J, Spengler U, B M, et al. Efficacy of retreatment after failed direct-acting antiviral therapy in patients with HCV genotype 1-3 infections. J Hepatol. 2021;19(1):195-198. doi:10.1016/j.cgh.2019.10.051.
Dore GJ, Altice F, Litwin AH, et al. Elbasvir-grazoprevir to treat hepatitis C virus infection in persons receiving opioid agonist therapy: a randomized trial. Ann Intern Med. 2016;165(9):625-634.
Dore G, Grebely J, Altice F, et al. Hepatitis C virus (HCV) reinfection and injecting risk behavior following elbasvir (EBR)/grazoprevir (GZR) treatment in participants on opiate agonist therapy (OAT): Co-STAR part B [abstract 195]. Presented at the Liver Meeting 2017; October 20–24, 2017; Washington, DC.
Doss W, Shiha G, Hassany M, et al. Sofosbuvir plus ribavirin for treating Egyptian patients with hepatitis C genotype 4. Journal of Hepatol. 2015;63(3):581-585.
Drazilova S, Janicko M, Skladany L, et al. Glucose metabolism changes in patients with chronic hepatitis C treated with direct acting antivirals. Can J Gastroenterol Hepatol. 2018;2018:6095097.
Drysdale K, Townley C, Mahomed F, Foster G. Effectiveness of therapy in 16,567 directly-acting antiviral treated people in England: High response rates in genotype 3 hepatitis C infection regardless of degree of fibrosis, but ribavirin improves response in cirrhosis. International Liver Congress. 2019.
Duque JC, Dejman A, Venkat V, Hernandez M, Roth D, Ladino MA. Acute interstitial nephritis following treatment with direct-acting antiviral agents in hepatitis C virus-infected patients: A case series. Clin Nephrol. 2021;95(1):22-27. doi:10.5414/CN110276.